Geode Capital Management, LLC Rain Therapeutics Inc. Transaction History

Geode Capital Management, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $1,548 - $2,248	1,843 Added 0.56%	331,059 $397,000
Q3 2023 Nov 13, 2023	BUY	$0.82 - $1.42 $4,710 - $8,157	5,745 Added 1.78%	329,216 $283,000
Q2 2023 Aug 11, 2023	BUY	$1.09 - $9.93 $176,120 - $1.6 Million	161,578 Added 99.81%	323,471 $388,000
Q1 2023 May 15, 2023	BUY	$7.77 - $12.47 $481,996 - $773,551	62,033 Added 62.12%	161,893 $1.41 Million
Q4 2022 Feb 13, 2023	BUY	$5.52 - $8.48 $140,274 - $215,493	25,412 Added 34.13%	99,860 $798,000
Q3 2022 Nov 14, 2022	BUY	$4.75 - $8.01 $6,208 - $10,469	1,307 Added 1.79%	74,448 $363,000
Q2 2022 Aug 12, 2022	SELL	$2.21 - $5.56 $270,811 - $681,316	-122,539 Reduced 62.62%	73,141 $406,000
Q1 2022 May 13, 2022	BUY	$5.07 - $13.68 $75,918 - $204,844	14,974 Added 8.29%	195,680 $992,000
Q4 2021 Feb 11, 2022	BUY	$11.91 - $17.0 $604,492 - $862,835	50,755 Added 39.06%	180,706 $2.33 Million
Q3 2021 Nov 12, 2021	BUY	$13.21 - $20.91 $29,497 - $46,692	2,233 Added 1.75%	129,951 $1.94 Million
Q2 2021 Aug 13, 2021	BUY	$15.08 - $20.3 $1.93 Million - $2.59 Million	127,718 New	127,718 $1.98 Million

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Geode Capital Management, LLC with notifications on news.